Research progress of Dickkopf1 related tumor metastasis

Abstract

Zhu Qiumei, Zhang Yong. Research progress of Dickkopf1 related tumor metastasis[J]. Journal of International Oncology, 2017, 44(6): 442-.

［1］ Massagué J, Obenauf AC. Metastatic colonization by circulating tumour cells［J］. Nature, 2016, 529(7586): 298-306. DOI: 10.1038/nature17038. ［2］Malladi S, Macalinao DG, Jin X, et al. Metastatic latency and immune evasion through autocrine inhibition of WNT［J］. Cell, 2016, 165(1): 45-60. DOI: 1016/j.cell.2016.02.025. ［3］史若愚. 分泌型蛋白DKK1在肝内胆管细胞癌侵袭转移中的作用及其机制研究［D］. 上海: 复旦大学, 2012. ［4］Lieven O, Knobloch J, Rüther U. The regulation of Dkk1 expression during embryonic development［J］. Dev Biol, 2010, 340(2): 256-268. DOI: 10.1016/j.ydbio.2010.01.037. ［5］王冰梅, 曾金镇, 刘英. Dkk1在器官发育及肿瘤发生中的调控作用［J］. 中国生物化学与分子生物学报, 2014, 30(8): 731-738. DOI: 10.13865/j.cnki.cjbmb.2014.08.01. ［6］彭裕辉, 许镒洧, 谢剑君. 血清DKK1在肿瘤临床应用中的价值［J］. 癌变·畸变·突变, 2014, 26(1): 79-81. DOI: 10.3969/j.issn.1004616x.2014.01.019. ［7］Yao L, Zhang D, Zhao X, et al. Dickkopf1promoted vasculogenic mimicry in nonsmall cell lung cancer is associated with EMT and development of a cancer stemlike cell phenotype［J］. J Cell Mol Med, 2016, 20(9): 1673-1685. DOI: 10.1111/jcmm.12862. ［8］陈亮. DKK1通过βcatenin/MMP7信号通路促进肝癌细胞迁移和侵袭［D］. 开封: 河南大学, 2014. ［9］于彬. Wnt通路抑制分子DKK1在肝细胞癌中异常高表达的分子机制［D］. 上海: 复旦大学, 2009. ［10］ Yu B, Yang X, Xu Y, et al. Elevated expression of DKK1 is associated with cytoplasmic/nuclear betacatenin accumulation and poor prognosis in hepatocellular carcinomas［J］. J Hepatol, 2009, 50(5): 948-957. DOI: 10.1016/j.jhep.2008.11.020. ［11］ Chen L, Li M, Li Q, et al. DKK1 promotes hepatocellular carcinoma cell migration and invasion through βcatenin/MMP7 signaling pathway［J］. Mol Cancer, 2013, 12: 157. DOI: 10.1186/1476459812157. ［12］胡海青, 阮洪军. 胃癌患者血清Dickkopf1的表达及其临床意义［J］. 肿瘤学杂志, 2012, 18(10): 750-752. ［13］蔡靓羽, 尹卫娟, 徐敏逸. 分泌蛋白DKK1（Dickkopf1）在胃癌患者血清及组织中的表达及其意义［J］. 中国现代医学杂志, 2014, 24(6): 1-8. ［14］ Mariz K, Ingolf JB, Daniel H, et al. The Wnt inhibitor dickkopf1: a link between breast cancer and bone metastases［J］. Clin Exp Metastasis, 2015, 32(8): 857-866. DOI: 10.1007/s1058501597501. ［15］ Saupe F, Schwenzer A, Jia Y, et al. TenascinC downregulates wnt inhibitor dickkopf1, promoting tumorigenesis in a neuroendocrine tumor model［J］. Cell Rep, 2013, 5(2): 482-492. DOI: 10.1016/j.celrep.2013.09.014. ［16］刘振, 潘光栋. DKK1与肿瘤发展［J］. 临床医学, 2014, 27(1下): 478-479. ［17］李明, 刘跃亮. 肿瘤细胞休眠的新机制研究进展［J］. 检验医学与临床, 2015, 12(22): 3437-3439. DOI: 10.3969/j.issn.16729455.2015.22.061. ［18］王爱云, 樊贤超, 陆茵, 等. 以中药诱导肿瘤休眠作为肿瘤防治策略的探讨［J］. 中草药, 2011, 42(3): 598-601. ［19］ Eyles J, Puaux AL, Wang X, et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma［J］. J Clin Invest, 2010, 120(6): 2030-2039. DOI: 10.1172/JCI42002. ［20］ Rcken M. Early tumor dissemination, but late metastasis: insights into tumor dormancy［J］. J Clin Invest, 2010, 120(6): 1800-1803. DOI: 10.1172/JCI43424. ［21］李书军, 和宇峥, 吕宝雷, 等. DKK1在食管癌组织中的表达及其生物学功能［J］. 世界华人消化杂志, 2011, 19(20): 2116-2122. ［22］腊蕾, 班武, 任青青. 外源性物质对Wnt通路抑制剂DKK的表达作用［J］. 中国医药指南, 2011, 9(30): 35-37. DOI: 10.15912/j.cnki.gocm.2011.30.276. ［23］蒙珊, 周芙玲, 白改改. Dickkopf（DKK1）在多发性骨髓瘤骨病中的作用及其靶向治疗的研究进展［J］. 肿瘤, 2011, 31(3): 273-276. DOI: 10.3781/j.issn.10007431.2011.03.017. ［24］ Mazon M, Masi D, Carreau M. Modulating dickkopf1: a strategy to monitor or treat cancer?［J］. Cancers (Basel), 2016, 8(7).pii: E62. DOI: 10.3390/cancers8070062. ［25］孙鑫. 乳腺癌MCF7细胞株中肿瘤干细胞的富集与鉴定及马钱子碱对其干预的实验研究［D］. 合肥: 安徽医科大学, 2012. ［26］陈永梅, 丁美萍, 陈照云. 中医药治疗癌症多靶点效应研究进展［J］. 山东中医杂志, 2012, 31(12): 917-919. ［27］黄玉栋, 郑雪峰, 刘航涛. 复方苦参注射液治疗肺癌骨转移疼痛的疗效及对Dickkopf1浓度的影响［J］. 世界中医药, 2015, 10(12): 1876-1879. DOI: 10.3969/j.issn.16737202.2015.12.010. ［28］陈瑞玉. 鳖甲煎丸对肝癌细胞Wnt信号通路βcatenin及抑制因子FrpHE、DKK1的影响［D］. 广州: 南方医科大学, 2011.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[4]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[5]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[6]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[7]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[8]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan.Progress of ferroptosis-related mechanisms in osteosarcoma[J]. Journal of International Oncology, 2024, 51(5): 308-311.
[9]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong.Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(4): 210-216.
[10]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[11]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[12]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150.
[13]	Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156.
[14]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174.
[15]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.

Research progress of Dickkopf1 related tumor metastasis

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments